Page last updated: 2024-11-12
monascorubrin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
monascorubrin: isolated from Monascus species [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12118084 |
| CHEMBL ID | 1215464 |
| CHEBI ID | 156408 |
| MeSH ID | M0513473 |
Synonyms (20)
| Synonym |
|---|
| CHEMBL1215464 |
| monascorubrin |
| CHEBI:156408 |
| (9ar)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-2h-furo[3,2-g]isochromene-2,9(9ah)-dione |
| 13283-90-4 |
| monasred |
| (9ar)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-2h-furo[3,2-g][2]benzopyran-2,9(9ah)-dione |
| prw98qj428 , |
| ccris 7225 |
| unii-prw98qj428 |
| 2h-furo(3,2-g)(2)benzopyran-2,9(9ah)-dione, 9a-methyl-3-(1-oxooctyl)-6-(1-propenyl)-, (r-(e))- |
| (9ar)-9a-methyl-3-(1-oxooctyl)-6-(1e)-1-propen-1-yl-2h-furo(3,2-g)(2)benzopyran-2,9(9ah)-dione |
| 2h-furo(3,2-g)(2)benzopyran-2,9(9ah)-dione, 9a-methyl-3-(1-oxooctyl)-6-(1e)-1-propen-1-yl-, (9ar)- |
| (9ar)-9a-methyl-3-octanoyl-6-[(e)-prop-1-enyl]furo[3,2-g]isochromene-2,9-dione |
| Q27286726 |
| 2h-furo[3,2-g][2]benzopyran-2,9(9ah)-dione, 9a-methyl-3-(1-oxooctyl)-6-(1e)-1-propen-1-yl-, (9ar)- |
| CS-0144836 |
| HY-N8492 |
| DTXSID101037235 |
| (r,e)-9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-2h-furo[3,2-g]isochromene-2,9(9ah)-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (6)
| Role | Description |
|---|---|
| food colouring | A food additive that imparts colour to food. In European countries, E-numbers for permitted food colours are from E 100 to E 199, divided into yellows (E 100-109), oranges (E 110-119), reds (E 120-129), blues and violets (E 130-139), greens (E 140-149), browns and blacks (E 150-159), and others (E 160-199). |
| biological pigment | An endogenous molecular entity that results in a colour of an organism as the consequence of the selective absorption of light. |
| fungal metabolite | Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. |
| Hsp90 inhibitor | An EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (5)
| Class | Description |
|---|---|
| azaphilone | Any member of a family of natural products which contains a 6H-isochromene-6,8(7H)-dione or an isoquinoline-6,8(2H,7H)-dione skeleton and its substituted derivatives thereof. |
| gamma-lactone | A lactone having a five-membered lactone ring. |
| triketone | A compound that contains three ketone functionalities. |
| polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID499312 | Binding affinity to HSP90 after 4 hrs by fluorescence polarization assay | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| AID499308 | Antiproliferative activity against human A431 cells after 72 hrs | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| AID499311 | Inhibition of yeast full-length recombinant HSP90 ATPase activity expressed in Escherichia coli strain BL21(DE3) assessed as inorganic phosphate release after 3 hrs | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| AID499310 | Antiproliferative activity against human IGROV1 cells after 72 hrs | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| AID499307 | Antiproliferative activity against human NCI-H460 cells after 72 hrs | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| AID499309 | Antiproliferative activity against human JR8 cells after 72 hrs | 2010 | Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16 | Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.16) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||